S-antigen transport inhibiting oligonucleotide polymers and methods
US11166976B2 · kind B2 · utility
0Cited by
19References
6Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 11, 2020 |
| Grant date | Nov 9, 2021 |
| Priority date | — |
| Expiry date | Sep 11, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2310/3519
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Various embodiments provide STOPS™ polymers that are S-antigen transport inhibiting oligonucleotide polymers, processes for making them and methods of using them to treat diseases and conditions. In some embodiments the STOPS™ modified oligonucleotides include an at least partially phosphorothioated sequence of alternating A and C units having modifications as described herein. The sequence independent antiviral activity against hepatitis B of embodiments of STOPS™ modified oligonucleotides, as determined by HBsAg Secretion Assay, is greater than that of a reference compound.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.